The Lalji Family ALS Award

The Lalji Family ALS Award is a global prize celebrating excellence in…

Words Maaike Dubbeldam.Published August 26, 2021
The Lalji Family ALS Award

The Lalji Family ALS Award is a global prize celebrating excellence in research for an individual or team of investigators who are making transformative breakthroughs in the science of repair of neurological function in ALS. The goal is to identify and recognize therapies and modalities to regain lost function in ALS patients.

 

Prize Criteria

The Lalji Family ALS Award is accepting nominations for individual or team of investigators who have made significant progress in the ALS field impacting the repair of neuronal degeneration in ALS. Examples include but are not limited to:
  • Identification of key modulators of axonal health and degeneration
  • Discoveries to explore changes in axonal transport
  • Novel methods to increase and improve endogenous neurogenesis
  • Cell therapies to target and improve neuronal and/or glial regeneration
  • Restoring nerve muscle communication
  • Immune system inhibition to decrease inflammation and improve neuronal regeneration
  • Discovery of intra-cellular mechanisms to enhance repair and regeneration

 

Timeline for Submission
  • Release Date: July 19, 2021
  • Nomination Due Date: September 10, 2021
  • Notification to successful candidate: Fall 2021
  • Presentation of award: Virtual 32nd International Symposium on ALS/MND December 2021

 

Download Nomination Form here.  Submit completed nomination form and supporting documents as a single PDF to healeycenterforals@mgh.harvard.edu

 

Award: $40,000 USD 

 

To learn more about the Sean M. Healey and AMG Center for ALS click here


Share

Related news

Results of TUDCA-study: No effect of investigated compound
Results of TUDCA-study: No effect of investigated compound
The TUDCA-ALS consortium has announced the first findings of the TUDCA study, […]
Amylyx: no effect after analyzing phase 3 study
Amylyx: no effect after analyzing phase 3 study
The pharmaceutical company Amylyx announced the first results of the PHOENIX study. […]
Tofersen receives positive opinion from CHMP (EMA)
Tofersen receives positive opinion from CHMP (EMA)
The Committe of Medicinal Products for Human Use (CHMP) of the European […]
Results ADORE study: no effect of medication
Results ADORE study: no effect of medication
The pharmaceutical company Ferrer has announced their first results of the ADORE […]